Lunsumio Side Effects

Generic name: mosunetuzumab

Medically reviewed by Drugs.com. Last updated on Jun 21, 2024.

Note: This document provides detailed information about Lunsumio Side Effects associated with mosunetuzumab. Some dosage forms listed on this page may not apply specifically to the brand name Lunsumio.

Applies to mosunetuzumab: intravenous solution.

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood tests are needed to check for unwanted effects.

Using this medicine while you are pregnant can harm your unborn baby. If you are a woman who can get pregnant, your doctor may do tests to make sure you are not pregnant before starting treatment. Use an effective form of birth control to keep from getting pregnant during treatment and for 3 months after the last dose. If you think you have become pregnant while using this medicine, tell your doctor right away.

This medicine may cause cytokine release syndrome (CRS) and infusion reactions. This may be life-threatening and requires immediate attention. Tell your doctor right away if you have a fever, chills, headache, nausea, lightheadedness, dizziness, fainting, skin rash, trouble breathing, or tiredness or weakness.

Check with your doctor right away if you have seizures, loss of balance, loss of consciousness, confusion, disorientation, difficulty with speaking, or slurred speech. These could be symptoms of a serious nerve problem.

This medicine may cause serious infections (eg, pneumonia, sepsis, upper respiratory tract infection). Check with your doctor right away if you have chest pain or tightness, fever or chills, confusion, cough or hoarseness, dizziness, fainting, fast heartbeat, lightheadedness, lower back or side pain, painful or difficult urination, sneezing, sore throat, or trouble breathing.

This medicine lowers the number of some types of blood cells in your body. Because of this, you may bleed or get infections more easily. To help with these problems, avoid being near people who are sick or have infections. Wash your hands often. Stay away from rough sports or other situations where you could be bruised, cut, or injured. Brush and floss your teeth gently. Be careful when using sharp objects, including razors and fingernail clippers.

This medicine may cause dizziness, confusion, tremors, or sleepiness. Do not drive or do anything else that could be dangerous until you know how this medicine affects you.

Check with your doctor right away if you have chest pain, cough, pain or swelling at the site of the tumor, tender or swollen lymph nodes, or trouble breathing. These may be symptoms of serious or worsening of tumor.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Lunsumio

Along with its needed effects, mosunetuzumab (the active ingredient contained in Lunsumio) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking mosunetuzumab:

Other side effects of Lunsumio

Some side effects of mosunetuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to mosunetuzumab: intravenous solution.

General adverse events

The most common adverse reactions with a frequency of 20% or greater were cytokine release syndrome , fatigue , rash , pyrexia , and headache.

Adverse reactions that required dosage interruption in greater than or equal to 5% of patients included neutropenia, infection, and cytokine release syndrome.^[Ref]

Dermatologic

• Very common (10% or more): Dry skin (16%), pruritus (21%), rash (39%)
• Common (1% to 10%): Skin exfoliation^[Ref]

Rash included rash erythematous, exfoliative rash, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, erythema, palmar erythema, dermatitis, and dermatitis acneiform.^[Ref]

Gastrointestinal

• Very common (10% or more): Abdominal pain (12%), diarrhea (17%), nausea (17%)^[Ref]

Abdominal pain included lower abdominal pain and abdominal discomfort.^[Ref]

Genitourinary

• Common (1% to 10%): Urinary tract infection^[Ref]

Urinary tract infection included urinary tract infection and acute pyelonephritis.^[Ref]

Hematologic

• Very common (10% or more): Decreased lymphocyte count (100%), decreased hemoglobin (68%), decreased neutrophils (58%), decreased platelets (46%), decreased white blood cells (60%)^[Ref]

Immunologic

• Very common (10% or more): Cytokine release syndrome (44%)^[Ref]

Metabolic

• Very common (10% or more): Uric acid increased (22%)
• Frequency not reported: Tumor lysis syndrome^[Ref]

Musculoskeletal

• Very common (10% or more): Arthralgia (11%), musculoskeletal pain (28%)^[Ref]

Musculoskeletal pain included back pain, myalgia, musculoskeletal chest pain, and neck pain.^[Ref]

Nervous system

• Very common (10% or more): Dizziness (12%), headache (32%), peripheral neuropathy (20%)
• Frequency not reported: Motor dysfunction^[Ref]

Headache included headache and migraine. Peripheral neuropathy included peripheral sensory neuropathy, paresthesia, dysesthesia, hypoesthesia, burning sensation, and neuralgia. Dizziness included dizziness and vertigo. Motor dysfunction included ataxia, gait disturbance and tremor.^[Ref]

Oncologic

• Frequency not reported: Tumor flare

Other

• Very common (10% or more): Chills (13%), decreased platelets (46%), decreased phosphate (78%), decreased magnesium (33%), edema (17%), fatigue (42%), increased glucose (42%), increased aspartate aminotransferase (39%), increased alanine aminotransferase (32%), increased gamma-glutamyl transferase (34), pyrexia (29%)
• Frequency not reported: EBV viremia, sepsis^[Ref]

Fatigue included asthenia, and lethargy. Edema included edema peripheral, peripheral swelling, face edema, swelling face, pulmonary edema, fluid overload, and fluid retention.^[Ref]

Psychiatric

• Very common (10% or more): Insomnia (12%)
• Frequency not reported: Mental status changes, anxiety^[Ref]

Renal

• Frequency not reported: Renal insufficiency^[Ref]

Respiratory

• Very common (10% or more): Dyspnea (11%), cough (22%), upper respiratory tract infection (14%)
• Frequency not reported: COVID-19, pneumonia^[Ref]

Cough includes cough, productive cough, and upper airway cough syndrome. Dyspnea included dyspnea and dyspnea exertional. Upper respiratory tract infection includes upper respiratory tract infection, nasopharyngitis, sinusitis, and rhinovirus infection.^[Ref]

See also:

Frequently asked questions

• What are monoclonal antibodies?

Further information

Lunsumio side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer